Nachtnebel, A. and Maran , P.R. and Alberti, C. and Garbaty , T. and Czeczot , J. (2012): Lenalidomide (Revlimid®) for the treatment of low /intermediate-1 risk myelodysplastic syndrome with chromosome 5q deletion. DSD: Horizon Scanning in Oncology 28.

Mathis, S. and Garbaty , T. and Czeczot , J. and Maran , P.R. and Alberti, C. and Nachtnebel, A. (2011): Eribulin (Halaven®) as third- or late- line mono-therapy for advanced/metastatic breast cancer. DSD: Horizon Scanning in Oncology 18.